Neuroanaesthesia & neurocritical care
Epilepsy After Antipsychotic Prescription in Survivors of Traumatic Brain Injury: A Population-Based Cohort Study
Authors' conclusion
We found no clear signal of a differential risk of epilepsy when comparing new prescriptions for haloperidol or risperidone with quetiapine among survivors of TBI.
Study context
- Population
- Adults ≥66 years without epilepsy who survived a first traumatic brain injury (TBI) admission and filled new antipsychotic prescriptions within 30 days after discharge; Ontario, Canada (2009–2021)
- Participants
- 1,204 adults
- Exposure
- Haloperidol or risperidone, each vs quetiapine, new prescription after TBI hospitalisation
- Haloperidoln = 202
- Risperidonen = 300
- Quetiapinen = 702reference
- Outcome
- New diagnosis of epilepsy
- Follow-up
- Up to 5 years following discharge
Methodological detailspopulation-based, inverse probability of treatment weighting
- Population-based
- Inverse probability of treatment weighting
Main finding
As reported in the abstract
up to 5 years
Each group vs quetiapineAdjusted hazard ratio (95% CI)
Haloperidol
0.73(0.39–1.34)
Risperidone
0.94(0.65–1.36)
Observational data: associations, not effects.
Further findings
Mortality · 5 years of follow-up
Original publication
Epilepsy After Antipsychotic Prescription in Survivors of Traumatic Brain Injury: A Population-Based Cohort Study. Crit Care Med. Published 21 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →